Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants

NCT00953927 is registered in ClinicalTrials.gov with Aeras as lead sponsor.

NCT NCT00953927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00953927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants
Lead sponsor
Aeras
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
Not reported
Enrollment
2,797 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis